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Abstract
Background: Intracameral cefuroxime is recommended as prophylaxis against postoperative endophthalmitis (POE)
following cataract surgery. Aprokam is the only licensed product for prophylaxis of POE, although unlicensed intracameral
cefuroxime may be administered using pre-filled syringes (PFS), either prepared in hospital by reconstituting cefuroxime
via serial dilution (prepared PFS), or commercially purchased (purchased PFS). This study aimed to estimate the potential
budget impact of using Aprokam over unlicensed cefuroxime for intracameral administration.
Methods: A budget impact model (BIM) was developed from UK NHS hospital perspective to estimate the economic
impact of adopting Aprokam compared with purchased PFS or prepared PFS for the prophylaxis of POE following
cataract surgery over a 5-year time horizon. The BIM incorporated direct costs only, associated with the acquisition,
delivery, storage, preparation, and administration of cefuroxime. Resource utilisation costs were also incorporated;
resource utilisation was sourced from a panel survey of hospital pharmacists, surgeons, and theatre nurses who are
involved in the delivery, storage, preparation, quality assurance, or administration of cefuroxime formulations. Unit
costs were sourced from NHS sources; drug acquisition costs were sourced from BNF. The model base case used a
hypothetical cohort comprising of 1000 surgeries in the first year and followed a 5.2 % annual increase each year.
Results: The model predicts Aprokam is cost saving compared with purchased PFS, with a modest increase
compared prepared PFS over 5 years. There are total savings of £3490 with Aprokam compared with purchased
PFS, driven by savings in staff costs that offset greater drug acquisition costs. Compared with prepared PFS, there
are greater drug acquisition costs which drive an increased total cost over 5 years of £13,177 with Aprokam,
although there are substantial savings in staff costs as well as consumables and equipment costs.
Conclusions: The lower direct costs of using Aprokam compared with purchased PFS presents a strong argument
for the adoption of Aprokam where purchased PFS is administered. The additional benefits of Aprokam include
increased liability coverage and possible reduction in dilution errors and contaminations; as such, in hospitals
where unlicensed prepared PFS is used, modest additional resources should be allocated to adoption of Aprokam.
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Background
Postoperative endophthalmitis (POE) is defined as an in-
flammation of the eye arising from a bacterial, fungal, or
parasitic infection during the postoperative period of sur-
gery [1]. This infection can originate from either a patient’s
own flora or from contaminated surgical instruments [2,
3]. POE is associated with adverse clinical outcomes that
include reduced vision and severe pain [1]. In the United
Kingdom (UK), the annual incidence of POE following
cataract surgery is estimated at 0.14 % [4].
In 2013, the European Society of Cataract and Refract-
ive Surgery (ESCRS) updated guidelines that recom-
mended use of intracameral cefuroxime as prophylaxis
against POE following cataract surgery [1]. This was
based on an ESCRS study conducted in nine European
countries including the UK (September 2003–January
2006), which demonstrated that use of intracameral
cefuroxime as prophylaxis against POE resulted in ap-
proximately a seven-fold reduction in the incidence of
POE compared with placebo (from 0.345 % to 0.049 %)
[5]. This recommendation is shared by the Royal College
of Ophthalmologists [6] and is also supported by a num-
ber of retrospective studies [1].
Despite the ECSRS recommendations, use of intra-
cameral cefuroxime has not been fully adopted. An
ESCRS survey of member ophthalmic surgeons con-
ducted in 2012 reported that the most common reasons
for not using intracameral cefuroxime during cataract
surgery were: the unavailability of the country/clinic spe-
cific protocol, unavailability of an approved preparation,
and concern over the risk of dilution errors [7]. These
major concerns are directly addressed by Aprokam®;
which, as per the UK National Health Service (NHS)
National Patient Safety Agency (NPSA) injectable risk
assessment proforma, is likely to be classified as a lower-
risk product [8]. Aprokam is available in 50 mg vials
comprising of cefuroxime that is reconstituted via a sim-
ple one-step process to a solution for intracameral injec-
tion of 1 mg cefuroxime constituting of 0.1 ml volume
of saline solution [7, 9]. Aprokam is currently the only
licensed product for POE prophylaxis, and received ap-
proval by the European Medicines Agency (EMA) in
2012 [9].
Prior to the availability of Aprokam, unlicensed formula-
tions of intracameral cefuroxime have been administered
using pre-filled syringes of cefuroxime (PFS) from a var-
iety of sources. Firstly, PFS is prepared in theatre by serial
dilution of 250 mg (or larger) vials of cefuroxime licensed
for injection or infusion. Secondly, some hospital phar-
macy departments prepare 10 mg/ml PFS (1 mg/0.1 ml)
(by serial dilution as above, but in a hospital pharmacy/
sterile supplies/pharmacy manufacturing unit [pmu] as
opposed to in theatre), and lastly, PFS are commercially
available from a variety of pharmaceutical sources.
Although the availability of a licensed alternative should
discourage use of these unlicensed formulations, the use
of PFS is still practiced. The protocol for the preparation
of PFS at the hospital is complex and varies among hospi-
tals [10, 11]. Preparation of sterile preparations (such as
PFS) should be carried out by trained staff (i.e. theatre
nurse or pharmacy technician) in a clean environment (i.e.
using a laminar hood or a glove box isolator) to ensure
quality, sterility, and safety of the preparation [12]. Non-
adherence to protocol [10] or inadequate mixing [13] of
cefuroxime in the syringe, which are likely with the
unlicensed preparation, can result in dilution errors and
contamination of purchased or prepared PFS. Dilution er-
rors can increase the dose of cefuroxime substantially
above the recommended 1 mg dose, with potential clinical
implications [11, 14, 15]. Cefuroxime concentration above
2.75 mg/mL has been shown to reduce the viability of hu-
man endothelial corneal cells [16].
Furthermore, serious macular detachment, macular in-
farction, macular oedema, corneal oedema, and haemor-
rhagic retinal Infarction are among the potential outcomes
arising from the administration of intracameral cefurox-
ime at doses that are higher than recommended [10, 11,
14, 15, 17]. Contamination is another serious consider-
ation, with incidences of POE following cataract surgery
caused by Fusarium species from contaminated cefurox-
ime reported in the literature [18]. Unlicensed cefuroxime
formulations may not provide adequate liability coverage
compared with Aprokam, with ESCRS guidelines stating
that, there should be awareness of the implications sur-
rounding liability when using unlicensed cefuroxime in-
jectable formulations [1].
The preparation of intracameral cefuroxime of any
type (Aprokam or PFS) incurs costs associated with staff,
consumables, equipment, and quality assurance. Whilst
the clinical arguments (lower risk of dilution errors) sup-
porting Aprokam over PFS are unequivocal, there re-
mains some reluctance among budget-holders to adopt
the licensed product available after consideration of the
relatively higher acquisition costs associated with Apro-
kam. However, there may be considerable cost savings
associated with staff time, consumables, and/or equip-
ment with Aprokam. There may also be additional costs
associated with the rare, but serious adverse clinical
events that might result from unlicensed cefuroxime
use, as well as reduced liability coverage for the hospital,
both of which are difficult to evaluate.
In addition to the clinical arguments, economic ana-
lyses have demonstrated the cost-effectiveness of cefur-
oxime compared with other antibiotics in preventing
POE following cataract surgery, further validating the
use of cefuroxime [19, 20]. However, no studies have
been reported that compare the cost differences of the
variety of cefuroxime injectable formulations available.
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One economic analysis of Aprokam to date, conducted
in a French private hospital, reported that the use of
Aprokam in cataract surgeries demonstrated cost savings
with improved clinical outcomes compared with cataract
operations without using cefuroxime [21].
The objective of this study was to develop a budget
impact model (BIM) to estimate the potential budget
impact of a UK National Health Service (NHS) hospital
adopting Aprokam in place of unlicensed cefuroxime
formulations (prepared PFS or purchased PFS) for the
prophylaxis of POE following cataract surgery. The model
estimated costs over a 5-year time horizon. Clinical out-
comes were not considered in this study and all cefurox-
ime formulations were assumed to have the same efficacy
and safety. The results of this study are of use for NHS
managers, payers, and clinicians, who can consider the re-
sults of this analysis in the wider context of cefuroxime
use, the license status and risk of dilution errors of each
cefuroxime formulation, when making decisions upon the
introduction of Aprokam in a clinical setting.
Methods
An economic model was developed in Microsoft Excel
to assess the potential budget impact of using Aprokam
compared with purchased PFS or prepared PFS for the
prophylaxis of POE following cataract surgery. Budget
impact was estimated over a 5-year time horizon (base
year 2013), from the perspective of a UK NHS hospital
setting. Since all three formulations are based on the
same active compound (cefuroxime), their efficacy and
safety profiles were assumed to be equal.
Modelling approach overview
The BIM incorporated direct costs only, associated with
the acquisition, delivery, storage, preparation, and admin-
istration of cefuroxime. The model took into account the
annual number of cataract surgeries to estimate the total
costs related to the prophylaxis of post-cataract surgery
POE. The analysis was carried out for a hypothetical co-
hort comprising of 1000 surgeries in the starting year and
followed by a 5.2 % annual increase. The annual increase
in the number of cataract surgeries was based upon NHS
data between 1998 and 2009 [6].
The model accounted for resources required to per-
form quality assurance during the preparation of PFS at
the hospital pharmacy (members of staff, consumables,
and equipment) as per the quality assurance protocols
for compounding sterile preparations published by the
Royal Pharmaceutical Society in the UK [22], the World
Health Organization [23], and the American Society of
Health-System Pharmacists [12]. These protocols recom-
mend ingredient identity, strength, sterility, purity and
environmental tests to be conducted. Quality assurance
was also considered at delivery (e.g. checking the labels
of purchased PFS) and during the storage of the prod-
ucts (e.g. temperature control).
Cost components were estimated based on resource
utilisation and resource unit costs (in 2013 GB £). Re-
source utilisation inputs were sourced from a panel survey
submitted to hospital pharmacists, surgeons, and theatre
nurses who are involved in the delivery, storage, prepar-
ation, quality assurance, or administration of cefuroxime
formulations used as a prophylaxis treatment against POE.
Unit costs were sourced from targeted literature searches
using publicly available sources.
Acquisition cost of cefuroxime Annual acquisition costs
were estimated for the number of Aprokam vials,
750 mg vials of Zinacef® (powdered cefuroxime), or
ready-to-use PFS purchased each year by the hospital,
and their unit costs. The annual number of Aprokam
vials and ready-to-use PFS of cefuroxime purchased by
the hospital were calculated from the number of cataract
operations performed. The number of vials of powdered
cefuroxime purchased was based on the number of cata-
ract operations, but also the number of individual doses
prepared with each vial, and the number of individual
preparations used for quality assurance purposes.
Cost of staff Cost of members of staff involved was
based on their hourly wages and their working time re-
lated to the ordering, delivery, storage, preparation, qual-
ity assurance, or administration of cefuroxime. Their
hourly wages were sourced from the annual salaries pub-
lished by the NHS, to which the methods for hourly
wage calculations published by the Personal Social Ser-
vices Research Unit were applied.
Cost of consumables These costs were related to the
provision of consumables required for the preparation
or the administration of intracameral cefuroxime, for ex-
ample syringes, syringe caps, needles, filters, connectors,
sterile bags, 0.9 % NaCl solution, heat-seal sterile
pouches, and sample tubes. Their unit costs were
sourced from various UK suppliers.
Cost of equipment These costs were related to storage
equipment (e.g. pharmacy fridge), preparation equipment
(e.g. beta-lactam laminar hood), and quality assurance
equipment (e.g. pH meter, osmometer, monochromator).
The model only accounted for the proportion of the
equipment value specifically dedicated to the delivery,
storage, preparation, or quality assurance of cefuroxime,
as informed by the panel survey. The corresponding value
of equipment was then extrapolated over a 5-year depreci-
ation time period, as per the guidelines of the finance
manual issued by the UK Department of Health [24].
Additionally, an annual maintenance cost corresponding
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to 12 % of the equipment value was applied [25]. Acquisi-
tion costs of equipment were sourced from various UK
suppliers.
Model settings
Base case values for the model settings are shown in
Table 1.
Drug-acquisition costs
Drug-acquisition costs were based on the unit costs of
Aprokam, PFS syringes (for purchased PFS), and Zinacef
(for prepared PFS), as published in the British National
Formulary (Table 2).
Model inputs
Cost inputs, presented in Table 3, show resource utilisa-
tion and unit costs used in the model.
Model assumptions
Based on the panel survey, the model assumed weekly
deliveries of cefuroxime products and the preparation of
PFS by pharmacy technicians in weekly batches using
750 mg vials. Quality assurance protocols for PFS pre-
pared at the hospital pharmacy are necessary to prevent
dilution errors and contamination and every hospital is
responsible for ensuring these protocols are in place.
The model therefore considered a default quality assurance
protocol based on the guidelines for compounding sterile
preparations published by the Royal Pharmaceutical Society
in the UK [22], the World Health Organization [23], and
the American Society of Health-System Pharmacists [12].
Each step of the quality assurance process requires a num-
ber of individual doses to be tested, and the model assumed
that altogether 7 individual doses of prepared PFS are ne-
cessary to conduct quality assurance tests during the prep-
aration of a weekly batch: one for the ingredient identity
test, one for the strength test, one for the purity test, and
four for the sterility test. These individual doses were then
discarded. As a result, the estimated number of individual
doses prepared with each Zinacef vial was 26. As per the
Aprokam Summary of Product Characteristics (SPC) rec-
ommendations, the model assumed that one single dose is
reconstituted per vial.
Since all three products contain the same active mol-
ecule, the model assumed the same efficacy between Apro-
kam and the comparators. Other outcomes may differ
between the three products, such as the risks of complica-
tions related to preparation errors, needle stick injuries and
wastage. However, due to lack of data, the model assumed
these risks to be negligible for all three products.
Results
Aprokam vs. purchased PFS
The base case analysis showed that when Aprokam re-
placed purchased PFS, the overall total cost over 5 years
was reduced by 4.8 % (total cost: £69,052 with Aprokam
and £72,541 with purchased PFS) (Table 4). Total cost
per cataract surgery was estimated at £12.5 with Apro-
kam and £13.1 with purchased PFS (Table 4). This corre-
sponded to total cost savings with the adoption of
Aprokam in place of purchased PFS of £3490 over
5 years and £0.6 per cataract surgery (Table 4).
The costs of both treatments were reported by re-
source category. The key driver for total cost savings
with Aprokam over 5 years was staff costs; with savings
of £10,401 compared with purchased PFS (Fig. 1). This
saving offsets the increase in acquisition and consum-
ables costs with Aprokam (Fig. 1). Staff costs comprised
of just 32.5 % of total costs with Aprokam, compared
Table 1 Base case settings of the BIM
Variables Details
Country and perspective United Kingdom; NHS and PSS perspective
Currency GB 2013 £
Time horizon 5 years
Intervention Aprokam vials of 50 mg, reconstituted into
one single 1 mg/0.1 mL individual dose
administered intracamerally by slow
injection into the anterior chamber of the
eye [9]. Resource utilisation inputs used in
the model for the reconstitution of Aprokam
follow the Aprokam SPC guidelines [9]
Comparators PFS of cefuroxime prepared in the pharmacy
hospital, using Zinacef 750 mg vials
Refrigerated ready-to-use PFS purchased by
the hospital from manufacturers
Number of cataract
surgeries in first year
Hypothetical cohort of 1000 cataract surgeries
performed in the first year
Annual increase in
cataract surgeries
Annual increase of 5.2 % in the number of
cataract surgeries. This is based on the
average annual increase in the number of
cataract surgeries performed within the NHS
in England between 1998 and 2009, as
reported by The Royal College of
Ophthalmologists [6]
BIM: budget-impact model; GB: Great Britain; NHS: National Health Service; PFS:
pre-filled syringes; PSS: Personal Social Services; SPC: Summary of
Product Characteristics
Table 2 Drug acquisition costs of Aprokam, purchased PFS, and
prepared PFS (2013 GB £)
Aprokam Purchased PFS Prepared PFS
Formulation Vial Syringe Vial (Zinacef)




Unit cost (2013 GB £) 7.95 [28] 7.00 [25] 2.34 [28]
BIM: budget-impact model; GB: Great British; PFS: pre-filled syringes; UK:
United Kingdom
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Table 3 Summary of resource utilization and unit cost/annual cost for each cefuroxime formulation (2013 GB £)
Resource utilization (number of
units or staff time in minutes)
Unit cost/annual
cost (2013 GB £)
Comments
Aprokam Purchased PFS Prepared PFS
Delivery
Pharmacy store manager (delivery) 2.5 1.5 2.5 45.8 [29, 30] Time related to the paperwork upon delivery
Nurse team manager 9.9 43.0 18.0 50.0 [30] Time related to weekly (prepared and purchased PFS)
or monthly (Aprokam) ordering of individual doses by
the theatre nurse to check the theatre stock (3 min),
order additional stock to the hospital pharmacy and
store it (15 min) and order additional stock from the
manufacturer directly (purchased PFS and Aprokam
only, 25 min)
Pharmacy store manager (QA during delivery) N/A 1.3 N/A 45.8 [29, 30] Time spent to check labelling of purchased PFS
Pharmacy store manager (transfer to storage area) 1.7 1.7 1.7 45.8 [29, 30] Time related to the transport from delivery area to
storage pharmacy storage
Storage
Pharmacy fridge N/A 1 N/A 132.0 [31] Upon delivery, only refrigerated PFS requires storage
in a fridge
Operating room fridge N/A 1 N/A 37.7 [32]
Porter (transport between storage areas) 9.6 9.6 9.6 20.0 [29, 30, 33] Time spent to transport cefuroxime from pharmacy
to theatre
Pharmacy technician (QA) N/A 0.5 N/A 45.8 [29, 30] Daily time spent for temperature control
Theatre nurse (QA) N/A 0.5 N/A 43.6 [29, 30] Daily time spent for temperature control
Preparation
Consumables
1 ml syringe 1 N/A 27 0.11 [34] The list of consumables required for the reconstitution
of Aprokam is based on the reconstitution protocol
described in Aprokam SPC related to one single dose
10 ml syringe N/A N/A 1 0.17 [34] The list of consumables used for the preparation of
PFS at the hospital pharmacy is based on feedback
from the panel survey. The list of consumables also
includes those related to quality assurance procedures
15 ml syringe 1 N/A N/A 0.20 [34]
The model assumes that 15 mL of saline solution are
required for the preparation of one individual PFS
50 ml syringe N/A N/A 2 0.56 [34]
Drawing up needle 2 N/A 2 0.02 [35]
0.2 μm filter N/A N/A 1 2.31 [34]
Connector N/A N/A 3 1.09 [36]
Sterile syringe cap N/A N/A 27 1.24 [37]
1 ml 0.9 % NaCl solution 5 N/A 408 0.01 [38]













Table 3 Summary of resource utilization and unit cost/annual cost for each cefuroxime formulation (2013 GB £) (Continued)
Equipment
Laminar hood N/A N/A 1 655.1 [40] Injectable syringes of cefuroxime are required to be
prepared in a controlled atmosphere
Pharmacy fridge N/A N/A 1 132.0 [31] During transfer to storage, storage, storage control and
any QA test performed during storage, only prepared
PFS requires. storage in a pharmacy fridge
Operating room fridge 1 1 1 37.7 [32] During transfer to storage, storage, storage control and
any QA test performed during storage, all cefuroxime
formulations requires storage in an operating room fridge
Staff
Pharmacy technician (preparation) N/A N/A 36.0 45.8 [29, 30] Time spent to perform the preparation of PFS in the pharmacy
Theatre nurse (transfer to storage) N/A 1.0 N/A 43.6 [29, 30] Time spent to transfer purchased PFS to storage area
Pharmacy technician (storage) N/A N/A 13.1 45.8 [29, 30] Time spent post-preparation to transfer to storage, conduct,
storage control and any other QA test performed during storage
Theatre nurse (preparation) 2.3 1.5 N/A 43.6 [29, 30] Time spent in the theatre for the reconstitution of Aprokam
or the preparation of purchased PFS
QA of prepared PFS
HPLC diode array detector (QA - Ingredient identity test) N/A N/A 1 46.9 [41] The list of these resources was based on the quality assurance
protocols for compounding sterile preparations published by
the Royal Pharmaceutical Society in the UK [22], the World
Health Organization [23], and the American Society of
Health-System Pharmacists [12], to prevent dilution errors
and contamination
Monochromator (QA - Ingredient identity test) N/A N/A 1 34.6 [42]
UV-vis spectrophotometer (QA - Ingredient identity test) N/A N/A 1 168.0 [43]
Head pharmacist (QA - Ingredient identity test) N/A N/A 2.5 49.4 [29, 30]
HPLC diode array detector (QA - Strength test) N/A N/A 1 46.9* [41]
Head pharmacist (QA - Strength test) N/A N/A 2.5 49.4 [29, 30]
Sample tube (QA- Purity test) N/A N/A 1 0.26 [44]
pH meter (QA- Purity test) N/A N/A 1 12.3 [45]
Osmometer (QA- Purity test) N/A N/A 1 73.7 [46]
Head pharmacist (QA - Purity test) N/A N/A 2.5 49.4 [29, 30]
Incubator (QA - Sterility test) N/A N/A 1 153.1 [47]
Head pharmacist (QA - Sterility test) N/A N/A 2.5 49.4 [29, 30]
Head pharmacist (QA - Environmental test) N/A N/A 2.5 49.4 [29, 30]
Head pharmacist (QA - Label and bagging) N/A N/A 2.1 49.4 [29, 30]
Administration
Surgeon 1.0 1.0 1.0 100.0 [29, 30] Time spent to intracamerally administer cefuroxime
Theatre nurse (QA) N/A N/A 1.0 43.6 [29, 30] Time spent to check prior to intracameral administration
Table legend: Cost inputs by phase (delivery, storage, preparation, and administration) of the cefuroxime preparation. Cost inputs are represented by resource utilisation (number of units or staff time in minutes) and
the cost of the unit/annual cost of the equipment. Resource utilisations for equipment and consumables inputs presented here are rounded to the nearest whole number. Furthermore, cost inputs are constituted by
consumables, equipment, and staff. Information pertaining to the cost inputs is presented in the right hand column of the corresponding cost inputs













with 45.3 % of the total costs with purchased PFS. Ac-
quisition costs represented more than half the total costs
for both treatments, although were responsible for a
greater proportion of the overall cost for Aprokam
(63.9 %) compared with purchased PFS (53.5 %) (Fig. 1).
Aprokam vs. prepared PFS
The base case analysis revealed that when Aprokam re-
placed prepared PFS, the overall total cost over 5 years
was increased by 23.6 % (total cost: £69,052 with Aprokam
and £55,875 with prepared PFS) (Table 5). Total cost per
cataract surgery was estimated at £12.5 with Aprokam
and £10.1 with prepared PFS (Table 5). This corresponded
to an incremental budget impact of £13,177 and an add-
itional cost of £2.4 per cataract surgery with Aprokam
over the 5 years compared with prepared PFS (Table 5).
By resource category, the key driver for the cost increase
with Aprokam over 5 years was acquisition costs; a budget
impact of £43,430 was predicted compared with acquisi-
tion costs incurred with prepared PFS (Fig. 2). Higher ac-
quisition costs with Aprokam were not compensated by
cost savings predicted over prepared PFS in the other
resource categories (consumables, equipment, and staff )
(Fig. 2). Staff costs represented 61.5 % of the total costs as-
sociated with prepared PFS and 32.5 % of the total costs
with Aprokam, leading to cost savings of £11,915 with
Aprokam (Fig. 2). Consumables and equipment were 6.2
times and 34.8 times more expensive with prepared PFS
over Aprokam, respectively, corresponding to cost savings
with Aprokam in these resource categories (Fig. 2).
Discussion
To our knowledge, this is the first published study to es-
timate the budget impact of introducing Aprokam in
place of unlicensed PFS cefuroxime formulations that
are either prepared at the hospital pharmacy or pur-
chased as a ready-to-use formulation for the prophylaxis
of POE following cataract surgery. This analysis was de-
veloped from a UK NHS hospital perspective to assist
clinicians, managers, and payers in making decisions
about adopting Aprokam. The outputs of the model pro-
vided an estimate of the direct economic consequences
of adopting Aprokam compared with two unlicensed
formations of intracameral cefuroxime.
This model estimated the budget impact of using Apro-
kam over a 5-year time horizon for a cohort of 1000 sur-
geries in the first year and assuming a 5.2 % annual
increase in cataract surgeries. The results showed that
Aprokam was a cost-saving alternative to purchased PFS.
Use of Aprokam was predicted to deliver total cost savings
of £0.6 per cataract surgery over purchased PFS, corre-
sponding to a reduction in total costs of 4.8 %. Aprokam,
however, was found in this analysis to have 23.6 % higher
Table 4 Costs of Aprokam compared with purchased PFS
(2013 GB £)
Aprokam Purchased PFS Difference
Overall total costs over 5 years
(2013 GB £)
69,052 72,541 −3490
Total costs per cataract surgery
(2013 GB £)
12.5 13.1 −0.6
GB: Great Britain; PFS: pre-filled syringes
Fig. 1 Base cast total cost of Aprokam and purchased PFS by resource category over 5 years (2013 GB £). GB: Great Britain; PFS: Pre-filled syringes
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overall total costs when compared with PFS prepared lo-
cally at the hospital pharmacy.
Cost savings with Aprokam compared with purchased
PFS were primarily driven by staff costs. The availability of
Aprokam as a ready to prepare formulation allows hospi-
tals to stock long-term supplies without product wastage.
Results from pharmacy managers in the panel survey sug-
gest purchased PFS would need to be ordered in at least
weekly to ensure there is a ready supply of PFS each week.
Aprokam accrued lower storage costs compared with pur-
chased PFS, as a consequence of the refrigeration required
with purchased PFS. In addition to the extra equipment
(pharmacy fridge and operating room fridge) costs, there
are costs associated with resource utilisation for transfers
between storage areas and surgery. Furthermore, there are
also costs associated with quality assurance steps that
should be undertaken with purchased PFS during delivery
and storage, unlike with Aprokam.
While there were extra costs related to the reconstitu-
tion of Aprokam as opposed to ready-to-use purchased
PFS which do not require any preparation (e.g. extra
staff time such as theatre nurse) and consumables
(syringes, drawing up needle, and 1 ml 0.9 % NaCl solu-
tion), the overall staff costs remained substantially
reduced.
In contrast, compared with prepared PFS, an incre-
mental budget impact of £13,177 over 5 years was esti-
mated with Aprokam. The key cost driver responsible
for the higher total cost was greater costs incurred with
the acquisition of Aprokam. These acquisition costs
were estimated to be over 65 times higher with Apro-
kam compared with prepared PFS. Preparation of PFS in
the hospital pharmacy is a complex procedure and re-
quires numerous steps as well as high amounts of con-
sumables, and specialised equipment (e.g. the use of a
laminar hood in order to ensure a controlled atmosphere
for the preparation of PFS cefuroxime).
Additionally, the risk of dilution errors associated with
prepared PFS [13] necessitates adherence to quality assur-
ance protocol. Published protocols recommend ingredient
identity, strength, sterility, purity, and environmental tests
to be performed for prepared PFS [12, 22, 23]. Such proto-
cols are not required for Aprokam. As a result, preparation
of PFS within the hospital requires extra consumables
(sample tube), equipment (high performance liquid chro-
matography [HPLC] diode array detector, and mono-
chromator, ultraviolet-visible [UV-vis] spectrophotometer,
pH meter, osmometer, incubator), as well as pharmacist
and nurse time. In addition, individual preparations of
cefuroxime used during quality assurance are discarded
and cannot be administered.
The economic impact of adopting Aprokam is just one of
a number of factors that should be used to guide decision-
making at the hospital. ESCRS guidelines recommend
Table 5 Costs of Aprokam compared with prepared PFS
(2013 GB £)
Aprokam Prepared PFS Difference
Overall total costs over 5 years
(2013 GB £)
69,052 55,875 13,177
Total costs per cataract surgery
(2013 GB £)
12.5 10.1 2.4
GB: Great Britain; PFS: pre-filled syringes
Fig. 2 Base cast total cost of Aprokam and prepared PFS by resource category over 5 years (2013 GB £). GB: Great Britain; PFS: Pre-filled syringes
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intracameral cefuroxime for the prophylaxis of POE for
patients undergoing cataract surgery [1]. Further, Apro-
kam is currently the only licensed intracameral cefurox-
ime formulation [1]. Use of unlicensed cefuroxime places
prescribers and the hospital with greater responsibility in
terms of liability as a result of harm to the patient, com-
pared with the use of licensed Aprokam [26].
There are also patient safety considerations to take
into account when selecting cefuroxime formulations.
Unlicensed formulations of intracameral cefuroxime ap-
pear to be associated with a high risk of dilution error –
both over- and under-dosing [13]. Dilution errors may
occur as a consequence of the multi-step dilution process
and overdosing up to 50 times the recommended concen-
tration has been reported, leading to postoperative inflam-
mation of the anterior chamber, corneal oedema, elevated
intraocular pressure, and cystoid macular oedema [10, 17].
Doses of intracameral cefuroxime lower than recom-
mended for POE prophylaxis can also result from dilution
errors with unlicensed formulations [13]. Such suboptimal
dosage can potentially lead to breakthrough POE or pro-
mote the development bacterial resistance [27].
When considering whether to adopt Aprokam, deci-
sion makers such as clinicians, NHS managers, and local
payers should consider the liability status of unlicensed
cefuroxime formulations and the higher probability of
dilution errors with prepared PFS as well as the eco-
nomic considerations. Unlicensed cefuroxime places the
patient at risk in terms of increased likelihood of receiv-
ing high doses that can result in complications such as
macular oedema. Furthermore, there is risk to the hos-
pital with the use of unlicensed treatments in terms of
reduced liability coverage. The lower estimated total
costs with Aprokam compared with PFS purchased as
ready-to-use formulation presents a strong case for the
introduction of Aprokam in hospitals where purchased
PFS is still used.
Study limitations
There are a number of limitations related to the study
methodology that may influence the results of this
budget impact analysis, and thus should be taken into
consideration when interpreting the cost estimates.
Firstly, the key inputs of the analysis are resource use
data provided by pharmacists, surgeons, and theatre
nurses who responded to the survey. Therefore, these in-
puts may not be applicable to all hospitals and may vary
should more robust sources be identified. Changes in
these inputs are likely to have an impact on the results
and their interpretation.
Due to lack of data, it was not possible to consider com-
plications due to dilution errors and contamination, in
terms of management costs (e.g. additional hospitalization
days) and their long-term consequences. For example,
dilution errors during the preparation of PFS have been
linked to higher risks of POE, IGS and TASS [13, 17]. Fur-
thermore, the model does not capture wastage related to
the different cefuroxime preparations. It is possible that
ready-to-use purchased PFS would lead to higher wastage
due to their shorter shelf life and their requirement of
refrigeration. It should be noted that not considering
complications and wastage is in favour of the comparators
and can be assumed to be a conservative approach. In
addition, the risk of needlestick injuries could not be
assessed for Aprokam and prepared PFS, which both re-
quire using needles during their preparation.
Finally, the analysis was conducted on a hypothetical co-
hort of 1000 cataract surgeries in the starting year,
followed by a 5.2 % annual increase in the number of sur-
geries. This setting is a key driver of the total costs re-
ported in this analysis over the considered time horizon,
although it is unlikely to impact the cost per surgery.
Conclusions
The lower overall total direct costs with Aprokam com-
pared with purchased PFS presents a strong argument for
the adoption of Aprokam in clinical settings where
unlicensed purchased PFS is still administered. Aprokam
presents with cost-savings, and increased liability coverage
compared with purchased PFS. Further, there is also the
assumption that the Aprokam is less likely to be associ-
ated with dilution errors and contaminations, although
these claims have not been empirically demonstrated. In
NHS hospitals where patients are still receiving unlicensed
prepared PFS, hospital managers and local payers should
strongly consider allocating additional financial resources
to achieve increased liability coverage with Aprokam.
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